Otsuka reports confirmatory VISIONARY data for Voyxact in IgAN

CURRENT FULL VERSION: Otsuka has reported new Phase 3 VISIONARY data for Voyxact, its APRIL-targeting antibody sibeprenlimab, in adults with IgA nephropathy, marking the next major milestone after the drug’s FDA accelerated approval in November 2025. That approval covered reduction of proteinuria in adults with primary IgA nephropathy at risk for disease progression, but the label also made clear that continued approval could depend on confirmatory evidence that the drug slows kidney function decline, measured by eGFR in the ongoing VISIONARY trial. The update lands during a broader period of portfolio activity for Otsuka, which has also agreed through Otsuka America to acquire Transcend Therapeutics for about $700 million upfront plus roughly $525 million in sales milestones, or about $1.225 billion total, in a deal expected to close in Q2 2026. (otsuka.co.jp)

The backstory matters here. Otsuka first reported positive interim Phase 3 results in October 2024, saying VISIONARY met its primary endpoint with statistically significant and clinically meaningful reduction in 24-hour urine protein-to-creatinine ratio after nine months of treatment. Otsuka followed with a June 2025 update highlighting those proteinuria data, and FDA then granted accelerated approval later that year. From the start, though, the bigger question for nephrologists was whether the proteinuria benefit would translate into preservation of kidney function over time. (otsuka.co.jp)

VISIONARY is a global, randomized, double-blind, placebo-controlled Phase 3 trial in biopsy-confirmed IgA nephropathy. ClinicalTrials.gov lists actual enrollment at 530 patients, with the main cohort including adults with eGFR of at least 30 mL/min/1.73 m², and identifies annualized eGFR slope over about 24 months as a key secondary objective. That design is important because it aligns with the confirmatory standard regulators increasingly want in IgAN: not just short-term proteinuria movement, but evidence that treatment changes the trajectory of renal decline. (clinicaltrials.gov)

Mechanistically, Voyxact stands apart from several other IgAN therapies because it targets APRIL, a cytokine involved in B-cell and plasma-cell biology and in production of galactose-deficient IgA1, which is implicated in disease pathogenesis. FDA reviewers described sibeprenlimab as binding APRIL to inhibit signaling that contributes to Gd-IgA1 production. That puts Voyxact in a different lane from targeted-release budesonide, which acts at gut-associated lymphoid tissue, and from endothelin-pathway drugs such as sparsentan and atrasentan, which have shown antiproteinuric benefit through hemodynamic and antifibrotic mechanisms. (accessdata.fda.gov)

Expert commentary around the program has consistently framed the drug as a potentially important upstream option in IgAN. In Otsuka’s approval announcement, University of Alabama at Birmingham nephrologist Dana Rizk, a VISIONARY investigator and steering committee co-chair, was cited in connection with the study program. Separately, nephrology coverage of Kidney Week 2025 highlighted that investigators and outside experts were looking ahead to 2026 renal outcomes data as the more practice-changing inflection point for sibeprenlimab. That’s because proteinuria reduction can support accelerated approval, but eGFR preservation is what typically carries more weight for long-term clinical confidence, payer positioning, and guideline uptake. (businesswire.com)

The company backdrop adds a little more context. While Voyxact is advancing in nephrology, Otsuka is also expanding elsewhere in branded biopharma. PharmaShots reported that Otsuka, via Otsuka America, has agreed to fully acquire Transcend Therapeutics to bolster its psychiatric and neurological portfolio. The transaction includes $700 million upfront and about $525 million in sales milestones, with closing expected in Q2 2026. If completed, it would add TSND-201, also known as methylone, a Phase 3 PTSD candidate with US patient recruitment underway, as well as follow-on prodrug work intended to improve efficacy, safety, and tolerability, with a candidate selected and nonclinical studies progressing toward an FDA IND filing. That deal is not directly related to Voyxact, but it does underscore that the company is making parallel bets across renal and CNS innovation.

Why it matters: Even for veterinary readers, this is a useful signal in renal therapeutics. Human nephrology is moving toward more precise, disease-driver-based treatment strategies, and IgAN has become a crowded proving ground for that shift. Voyxact’s progress suggests regulators and clinicians are increasingly willing to reward therapies that show both biologic plausibility and confirmatory renal outcomes. It also shows how competitive the field has become: sparsentan has already generated confirmatory kidney outcomes data, targeted-release budesonide has guideline momentum, and other candidates such as Vertex’s povetacicept and Takeda’s mezagitamab are advancing through the pipeline. Otsuka’s simultaneous willingness to spend heavily outside nephrology, including on the planned Transcend acquisition, also highlights how large biopharma groups are trying to build diversified specialty portfolios rather than relying on a single franchise. (businesswire.com)

For veterinary professionals, the broader takeaway is less about immediate companion-animal use and more about where kidney drug development is heading. The field is increasingly organized around validated biomarkers, adaptive regulatory pathways, and therapies aimed at upstream immune mechanisms rather than only downstream symptom control. That pattern often matters when assessing future translational opportunities in immune-mediated renal disease, biomarker strategy, and how specialty care may evolve for pet parents facing chronic kidney conditions in dogs and cats. This last point is an inference based on the direction of human renal R&D rather than a direct claim from the cited sources. (businesswire.com)

What to watch: The next key step is the full public presentation or publication of the new VISIONARY dataset, including the exact magnitude of eGFR benefit, subgroup findings, and safety profile, followed by any FDA action tied to conversion from accelerated to traditional approval and any updates to treatment sequencing in IgAN guidelines and practice. Separately, watch whether Otsuka closes the Transcend deal on the expected Q2 2026 timeline and how that acquisition shapes the company’s broader specialty pipeline priorities. (businesswire.com)